Related posts
Oil sinks in choppy sessionMild and mixed before earningsUS-China tensions weigh on marketsThis summary was created by AI, based on 2 opinions in the last 12 months.
Experts have differing opinions on Molson Coors Brewing Company's stock. One expert is shocked by the 24% decline in the last 3 months and believes the company's drinks will be hurt by the popularity of GLP-1 weight-loss drugs. However, another expert disagrees and would buy more shares if it weren't for the trend. Growth has slowed and there is a negative sentiment towards alcohol both domestically and internationally.
Growth has slowed in recent months and people here and abroad have turned hard against alcohol.
This is one of the top brewers, but like all the others in the beer industry, Molson Coors is struggling. Their market is extremely mature, with declining consumption. Molson has bought some craft brewers but those companies are getting expensive. Very low multiple and generates good cash flow. They are using free cash to pay down debt. But it's difficulty to find new ways to grow. It's a tough call to say to buy because the company looks relatively cheap, well-managed but maybe not likely to grow much. They're entering into joint ventures with cannabis companies, experimenting with infused beverages. He is not sure how big the market will be for these products. It might get very crowded very quickly. For the next few years, for Molson Coors, these are small projects--tiny in the grand scheme of things.
Brewers are struggling with declining sales. Valuation is still on the rich side, mainly because of declining margins. Doesn’t have EM exposure that you’d like to see. Be cautious. Compares poorly to its peers. (Analysts’ price target is $77.43.)
Weaker volume sales in US. Core business is US and Canada. Free cash flow is about 10% free cash flow yield. Concern that beer growth is slowing. They’ve been smart and done a joint venture with a marijuana company. This is a good level to buy.
A defensive name. A company that looks to be acquired. The stock looks goods now on the pullback. Steady dividend and good yield. Maybe the fact that marihuana is being legalized affected the price of the stock and its multiples. A boring traditional business as it is
Had a terrific 2015-2016 and a “not so good” 2017. Thinks that was part of a rotation out of defensive, boring stocks into sexy technology names. This is not going to be a fast grower. It recently acquired Millers Coors, a much bigger company. Not a growth story, but more of a cost control story. There is a lot of value in this. It is worth $100 a share, and perhaps $125 in a couple of years once it pays down the debt, as well as a potential acquisition by Heineken.
It is an interesting company. If we are thinking about being late cycle, there are a few industries that are recession proof, like alcohol. They have a nice dividend.
She is not a fan right now. There is incredible, tough competition in beverages.
Molson Coors Brewing Company is a American stock, trading under the symbol TAP-N on the New York Stock Exchange (TAP). It is usually referred to as NYSE:TAP or TAP-N
In the last year, 2 stock analysts published opinions about TAP-N. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Molson Coors Brewing Company.
Molson Coors Brewing Company was recommended as a Top Pick by on . Read the latest stock experts ratings for Molson Coors Brewing Company.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Molson Coors Brewing Company In the last year. It is a trending stock that is worth watching.
On 2024-12-13, Molson Coors Brewing Company (TAP-N) stock closed at a price of $61.07.
He's shocked by their 24% decline in the last 3 months. The street believes that all their drinks will be hurt by the popularity of the GLP-1 weight-loss drugs, but he disagrees. He would buy more shares, but it's hard to buck the GLP-1 trend.